Cloacogenic carcinoma
MONDO:0004129An anal carcinoma arising from the transitional zone of the anal canal.
Also known as: anal canal cloacogenic cancer, anal canal cloacogenic carcinoma, anal cloacogenic carcinoma, cloacogenic anal carcinoma, cloacogenic carcinoma, cloacogenic carcinoma (morphologic abnormality), cloacogenic carcinoma of anus, cloacogenic carcinoma of the anus
2891 clinical trials for this condition and its sub-types, 10 tagged with Cloacogenic carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Could less be more? new trial tests gentler treatment for anal cancer
Disease control OngoingThis phase II trial is testing whether a lower dose of chemotherapy plus radiation can work as well as the standard dose for early-stage anal cancer. The study includes 252 adults with T1-2N0M0 anal cancer. The goal is to see if the gentler approach controls the disease while imp…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo therapy aims to fight metastatic anal cancer
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (carboplatin and paclitaxel) helps people with metastatic anal cancer live longer without their disease getting worse. About 205 adults with inoperable or recurrent anal cancer …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Immunotherapy after Chemo-Radiation may keep anal cancer at bay
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug nivolumab after standard combined modality therapy (chemo and radiation) can improve outcomes for patients with high-risk stage IIB-IIIC anal cancer. About 344 participants will receive nivolumab or a placebo. The m…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Immunotherapy combo shows promise for tough anal cancer
Disease control OngoingThis study tests two immunotherapy drugs, nivolumab and ipilimumab, in people with anal cancer that has spread and not responded to prior treatment. The goal is to see if these drugs can shrink tumors or slow cancer growth. About 143 adults with advanced squamous cell carcinoma o…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a Mid-Treatment scan make radiation smarter?
Knowledge-focused OngoingThis study is testing whether doing a special PET scan during radiation treatment can help doctors adjust the plan to better target tumors and spare healthy tissue. It involves 90 adults with cervical, vulvar, esophageal, or anal cancer. The goal is to see if this approach improv…
Phase 2 • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC